Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCORI Research Priorities Too Broad For Meaningful Feedback, AdvaMed Says

This article was originally published in The Gray Sheet

Executive Summary

The device industry, professional societies and other stakeholders weigh in on how the Patient-Centered Outcomes Research Institute should shape its national priorities and research agenda.

You may also be interested in...



PCORI Unveils Process For Generating Future Research Topics

The Patient-Centered Outcomes Research Institute will seek broad input on its future research agenda. Advisory panels will help prioritize suggestions, and the institute's board of governors will make the final decision on research topics available for funding.

PCORI Will Ask Research Funding Applicants To Include Ideas For Disseminating Results

Draft checklist would ask researchers for ideas on involving stakeholders, “engagement points” and ways to disseminate research results, indicating PCORI will ask researchers to think outside of their typical approaches such as journal publication or scientific meetings.

PCORI Draft Research Agenda Offers Only Broad Areas Of Study

The Patient-Centered Outcomes Research Institute issues its draft national priorities and research agenda for comment Jan. 23. Rather than specific research items, the list contains five broad areas designed to elicit the greatest amount of input from stakeholders on what projects should be funded.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel